235 related articles for article (PubMed ID: 10506596)
1. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Jones SE; Khandelwal P; McIntyre K; Mennel R; Orr D; Kirby R; Agura E; Duncan L; Hyman W; Roque T; Regan D; Schuster M; Dimitrov N; Garrison L; Lange M
J Clin Oncol; 1999 Oct; 17(10):3025-32. PubMed ID: 10506596
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
O'Shaughnessy JA; Tolcher A; Riseberg D; Venzon D; Zujewski J; Noone M; Gossard M; Danforth D; Jacobson J; Chang V; Goldspiel B; Keegan P; Giusti R; Cowan KH
Blood; 1996 Mar; 87(6):2205-11. PubMed ID: 8630380
[TBL] [Abstract][Full Text] [Related]
4. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
Runowicz CD; Mandeli J; Speyer JL; Wadler S; Hochster H; Garrison L; Holland JF
Am J Obstet Gynecol; 1996 Apr; 174(4):1151-9; discussion 1159-60. PubMed ID: 8623842
[TBL] [Abstract][Full Text] [Related]
6. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
9. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
O'Reilly SE; Gelmon KA; Onetto N; Parente J; Rubinger M; Page RA; Plenderleith IH
J Clin Oncol; 1993 Dec; 11(12):2411-6. PubMed ID: 8246030
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer.
Kobrinsky NL; Sjolander DE; Cheang MS; Levitt R; Steen PD
J Clin Oncol; 1999 Nov; 17(11):3426-30. PubMed ID: 10550137
[TBL] [Abstract][Full Text] [Related]
14. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
15. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen.
Murren JR; Gollerkeri A; Anderson S; Lutzker S; Del Prete S; Zelterman D; Garrison L; Smith B
Yale J Biol Med; 1998; 71(5):355-65. PubMed ID: 10527363
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.
Roman-Unfer S; Bitran JD; Garrison L; Proeschel C; Hanauer S; Schroeder L; Johnson L; Klein L; Martinec J
Exp Hematol; 1996 Jun; 24(7):823-8. PubMed ID: 8647233
[TBL] [Abstract][Full Text] [Related]
18. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
Furman WL; Rodman JH; Tonda ME; Luo X; Arnold B; Marina N; Garrison L; Hanna R; Pratt CB; Meyer WH
Cancer Chemother Pharmacol; 1998; 41(3):229-36. PubMed ID: 9443640
[TBL] [Abstract][Full Text] [Related]
20. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
